The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment
-
Ariceta Iraola, Gema (Hospital Universitari Vall d'Hebron)
;
Dixon, B.P. (Renal Section. Department of Pediatrics. University of Colorado School of Medicine) ;
Kim, S.H. (Department of Pediatrics. Pusan National University Children's Hospital) ;
Kapur, G. (Faculty of Pediatric Sciences. Central Michigan University. Mount Pleasant) ;
Mauch, T. (Department of Nephrology and Hypertension. Division of Pediatrics. University of Utah) ;
Ortiz, S. (Clinical and Non-Clinical Pharmacology. Alexion Pharmaceuticals Inc.) ;
Vallee, M. (Biostatistics. Alexion Pharmaceuticals Inc.) ;
Denker, A.E. (Clinical Development. Alexion Pharmaceuticals Inc.) ;
Kang, H.G. (Division of Pediatric Nephrology. Department of Pediatrics. Seoul National University College of Medicine) ;
Greenbaum, L.A. (Division of Pediatric Nephrology. Emory University School of Medicine and Children's Healthcare of Atlanta) ;
Lovell, H. ;
Muff-Luett, M. ;
Malone, K. ;
Adeagbo, O. ;
Wilkerson, A. ;
Fraga Rodríguez, Gloria María (Institut d'Investigació Biomèdica Sant Pau) ;
Sarri, S. ;
Cheong, H.I. ;
Ahn, Y.H. ;
Han, K.H.
visitante ::
identificación
Subscribirse to this discussion. You will then receive all new comments by email.
